STOCK TITAN

BlackRock Health Sciences: Final tender offer amendment

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC TO-I/A

Rhea-AI Filing Summary

BlackRock Health Sciences Term Trust (BMEZ) filed a final amendment concerning its tender offer, saying it was submitted to report the offer’s results. The offer sought to repurchase up to 5% of issued and outstanding common shares for cash at 98% of net asset value per share, determined at the close of the New York Stock Exchange’s regular trading session on the next day NAV was calculated after the offer expired.

Repurchase cap Up to 5% of issued and outstanding common shares Tender offer terms
Cash offer price 98% of NAV per share NAV determined at the close of the regular trading session on the next day NAV was calculated after the offer expired
tender offer regulatory
"an offer by the Fund to repurchase up to 5%"
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
net asset value financial
"98% of the net asset value per Share"
Net asset value is the total value of an investment fund's assets minus any liabilities, divided by the number of shares or units outstanding. It represents the per-share worth of the fund, similar to how the value of a house is determined by its total worth after debts are subtracted. Investors use it to gauge the true value of their holdings and to compare different investment options.
Rule 13e-4 regulatory
"pursuant to Rule 13e-4"
Rule 13e-4 is a U.S. securities regulation that governs offers by a company or its insiders to buy back shares or take the company private, requiring clear, public disclosures and procedural safeguards for shareholders. It matters to investors because it forces the party making the offer to explain the deal terms, financial impacts, and alternatives so shareholders can judge whether the price and process are fair—much like a rulebook that makes a seller show detailed terms before a home sale to avoid surprises.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BMEZ shares did the tender offer seek to repurchase?

The offer sought to repurchase up to 5% of issued and outstanding common shares.

How was the BMEZ tender offer price determined?

The cash price was 98% of NAV per share, based on NAV determined at the close of the regular trading session on the next day NAV was calculated after the offer expired.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT

Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 2)

 

 

BlackRock Health Sciences Term Trust

(Name of Subject Company (Issuer))

BlackRock Health Sciences Term Trust

(Names of Filing Person(s) (Issuer))

Common Shares of Beneficial Interest, Par Value $0.001 per share

(Title of Class of Securities)

09260E105

(CUSIP Number of Class of Securities)

John M. Perlowski

BlackRock Health Sciences Term Trust

50 Hudson Yards

New York, New York 10001

(800) 882-0052

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person(s))

 

 

Copies to:

 

Margery K. Neale, Esq.  
Elliot J. Gluck, Esq.   Janey Ahn, Esq.
Willkie Farr & Gallagher LLP   BlackRock Advisors, LLC
787 Seventh Avenue   50 Hudson Yards
New York, New York 10019   New York, New York 10001

 

 

October 16, 2026

(Date Tender Offer First Published, Sent or Given to Security Holders)

 

 

 

☐

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which this statement relates:

 

  ☐

third-party tender offer subject to Rule 14d-1.

  ☒

issuer tender offer subject to Rule 13e-4.

  ☐

going-private transaction subject to Rule 13e-3.

  ☐

amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☒

 

 
 


This Amendment No. 2 (this “Final Amendment”) relates to the Issuer Tender Offer Statement on Schedule TO originally filed on October 16, 2026, as amended and supplemented by Amendment No. 1 to the Issuer Tender Offer Statement on Schedule TO filed on November 18, 2026 (together, the “Schedule TO”), by BlackRock Health Sciences Term Trust, a Maryland statutory trust (the “Fund”), pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with an offer by the Fund (the “Offer”) to repurchase up to 5% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (the “Shares”), in exchange for cash at a price equal to 98% of the net asset value (“NAV”) per Share determined as of the close of the regular trading session of the New York Stock Exchange, the principal market on which the Shares are traded, on the next day the NAV is calculated after the Offer expires, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 16, 2026 (the “Offer to Purchase”), and in the related Letter of Transmittal, copies of which were previously filed as Exhibits (a)(1)(i) and (a)(1)(ii), respectively, to the Schedule TO.

This is the Final Amendment to the Schedule TO and is being filed to report the results of the Offer and to update Item 12 of the Schedule TO to include a press release announcing the final results of the Offer. A copy of the press release is attached hereto as Exhibit (a)(5)(iii). Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Offer to Purchase or the Schedule TO.

The following information is furnished to satisfy the requirements of Rule 13e-4(c)(4) under the Exchange Act:

 

  1.

The Offer expired at 5:00 p.m. Eastern time, on November 18, 2026.

 

  2.

The Offer was oversubscribed. Therefore, in accordance with the terms of the Offer, the Fund will purchase Shares from all tendering shareholders on a pro rata basis, after disregarding fractions, based on the number of Shares properly tendered. 13,178,845 Shares of the Fund were validly tendered and not withdrawn prior to the expiration of the Offer, and 3,125,070 of those Shares were accepted for repurchase by the Fund in accordance with the terms of the Offer.

 

  3.

The Shares will be repurchased at a price of $17.8458, which is equal to 98% of the Fund’s NAV per Share as of November 19, 2026.

Except as specifically provided herein, this Final Amendment does not modify any of the information previously reported in the Schedule TO, as amended, or the Letter of Transmittal.

Item 1 through Item 9 and Item 11

The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference into this Final Amendment in answer to Item 1 through Item 9 and Item 11 of the Schedule TO.

Item 10. Financial Statements

(a) The audited annual financial statements of the Fund dated December 31, 2025 and the schedule of investments of the Fund dated December 31, 2025, both filed with the SEC on EDGAR on Form N-CSR on March 5, 2026, are incorporated by reference. The unaudited semi-annual financial statements of the Fund dated June 30, 2026 and the schedule of investments of the Fund dated June  30, 2026, both filed with the SEC on EDGAR on Form N-CSRS on September 3, 2026, are incorporated by reference.

(b) Not applicable.

Item 12(a). Exhibits

Item 12(a) of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(5)(iii) Press release issued on November 19, 2026 is filed herewith.

Item 12(c). Filing Fees

Filing Fee Exhibit is filed herewith.

Item 13. Information Required By Schedule 13E-3

Not applicable.


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

BlackRock Health Sciences Term Trust
By:  

/s/ John M. Perlowski

  Name: John M. Perlowski
  Title: President and Chief Executive Officer
  Dated: November 19, 2026


Exhibit Index

 

Exhibit
Number
 

Description

(a)(5)(iii)   Press release issued on November 19, 2026
  Filing Fee Exhibit

Keep reading